Dr. Timothy Wilt, a member of the United States Preventive Services Task Force, stood in front of the American Urological Association audience and explained why the task force could not recommend that men undergo routine PSA screening. At most, he explained, the test had been shown to benefit one out of 1000 men. Meanwhile, the test would cause hundreds of men to experience anxiety, and scores of them to experience impotence and incontinence from unnecessary treatments.

Twenty minutes later, I stood behind the same podium and asked the audience members to raise their hands if they disagreed with the task force’s conclusion. Ninety percent expressed their skepticism. What happened in the time between Wilt’s presentation and mine reveals a great deal about why experts cannot agree whether screening tests, like the PSA in middle-age men or mammograms in 40-year-old women, bring more benefit than harm, and about what psychological forces impede our ability, as a society, to figure out what basic bundle of healthcare services all insurance companies ought to pay for.

Wilt’s presentation was a model of scientific clarity. He explained that only two randomized clinical trials were conducted with enough scientific rigor to provide useful estimates of whether the PSA test saves lives. One trial showed no benefit and the other revealed the one in 1000 number which the task force took as the best case scenario. Wilt was followed on stage by Ruth Etzioni, a biostatistician at the Fred Hutchinson Cancer Research Center in Seattle.  Etzioni presented a statistical model suggesting that the PSA test benefited many more than one in 1000 men.

Psychology was already at work. After hearing two scientific presentations, one emphasizing randomized trials (which physicians typically considered to be the gold standard of medical evidence) and another focusing on statistical models (which physicians typically consider too abstract to capture clinical reality), urologists found themselves embracing the scientific merits of the statistical models.

In a famous1979 study, 3 Stanford psychologists recruited students who held strong opinions about the death penalty, and exposed each of them to two hypothetical research studies, one suggesting that capital punishment deters crimes and one pointing to the opposite conclusion.  All saw critiques of each study, as well as responses to the critiques.  The result?  The more information students saw, the more polarized their opinions became.  Pro-death penalty students became even more in favor of the death penalty, while those previously opposed to the death penalty became even more opposed to it.

Not liking the task force’s conclusion, urologists viewed the randomized clinical trials with deep skepticism, a skepticism they did not direct towards the equally shaky statistical model. We see what we hope to see.

One more presenter stepped behind the podium before my presentation: Capt. Mark Kelly, retired NASA astronaut and, just as famously, supportive spouse of Rep. Gabby Giffords. Kelly charmed the audience with the story of how he was diagnosed with prostate cancer four years earlier, at the age of 44, and was then cured by a urologist who removed his cancerous gland. Looking no worse for the wear, and joking about the benefits of not having to go to the bathroom in the middle of the night, Kelly was living proof of the benefits of PSA testing.

But did the PSA test save Kelly’s life? Psychology was at work again. The task force estimate of one in 1000 lives saved was not established by measuring how many men, out of 1000, are diagnosed with prostate cancer by the PSA test but, instead, by estimating how many of those 1000 men are not only diagnosed but are also cured of a cancer that would otherwise have killed them. When a 71-year-old man has his prostate removed to treat localized cancer, it is impossible to know whether his life was saved by the procedure. If he dies at age 78 of a heart attack, for instance, no one can say for certain whether his prostate cancer, if untreated, would have killed him before then. The vast majority of men who undergo prostatectomy, in fact, do not live longer because of the operation. But here is where psychology comes into play: virtually every man who undergoes this arduous procedure is convinced that the operation has saved his life.  Those who experience impotence or incontinence from the treatment are likely even more convinced of its benefits.  How else can they overcome the cognitive dissonance of willingly undergoing a procedure with such significant side effects?

We may never know the true benefits of PSA screening. It is almost impossible to conduct a clinical trial in which those men randomized to the “control group” are willing to forego screening tests for the duration of the trial, meaning that the trials will inevitably underestimate the benefits and harms of PSA screening. That leaves us with statistical models that will only confirm people’s pre-existing biases.

Our best hope is to conduct high-quality randomized trials of newer, potentially better screening tests, trials in which men in the control group are not allowed to obtain the new screening test until the trial is complete. No matter how promising the new test appears to be, physicians and insurance companies need to agree not to offer, or pay for, the test outside of the trial.

Meanwhile, men need to decide whether the unproven benefits of the PSA test outweigh its proven harms. This is no simple decision, as Capt. Kelly’s story makes clear.

At a 50-year-old physician myself, now six years older than Kelly was at the time of diagnosis, I have decided to hold off on PSA testing. Meanwhile, I will stick with tests that yield more certain benefits. That means the word colonoscopy will be taking on new relevance in my life very soon.

Peter Ubel is a physician, behavioral scientist and author of Pricing Life: Why It’s Time for Health Care Rationing and Free Market Madness. He teaches business and public policy at Duke University. Peter’s new book, Critical Decisions will be available in the fall of 2012. You can follow him on his personal blog.

Share on Twitter

7 Responses for “Is Prostate Cancer Screening Truly Harmful?”

  1. Rob says:

    I turn 50 soon and am facing that same spectre called a colonoscopy. This is a very well-written post, and as a physician who has to discuss and recommend the test for others, I have seen the cognitive dissonance at work. My father had prostate CA at an older age and so I am stuck deciding if that family history is enough to get tested. He had XRT and has had multiple complications since then. The reality of applying the science to a single individual in the exam room is a daunting and often confusing task.

  2. Steve says:

    Question #1: Who funds the USPSTF? (Hint: It might be the gummint)
    Question #2: Who is trying to cut costs for publicly-funded healthcare? (Hint: This might also be the gummint)
    Question #3: Is the goal in Question #2 served better by the going along with the USPSTF recommendations, or by continuing to test those you, as a provider, perceive to be at risk?
    Questions#4: Should I question the recommendations of the USPSTF for other screenings, such as breast cancer?

  3. Steve says:

    While I do not defend it as logic, it certainly is a line of reasoning, whether you agree with it, or not. In no respect is it ad hominem, as the Task Force is mentioned in every discussion I hear, if only to balance other recommendations. In some instances, such as cervical cancer screening, the differences aren’t as pronounced among ACS, ACOG and USPSTF. What I do hear is the media trumpeting pronouncements from the Task Force for certain screening tests, and not responsibly providing other arguments. If you look at the Task Force evidence update, you might also see what the British Medical Journal saw, and that is the evidence is not good quality all around. In fact, while the screening tests (PSA wasn’t even used in the first years of at least one widely quoted study), may not affect mortality, the interventions, i.e. prostatectomy, certainly do. Despite the Task Force’s disclosure that they are using external draft reviewers for the report, and that they have no relationship with the Task Force, I’m uncertain what relationship they have with AHRQ, the contractor, and another government entity. It would serve everyone well to be aware of who issues prevention, screening and treatment guidelines and be a little more skeptical. BTW, the cut-off for treatment, harmful, or otherwise is mentioned in studies of 4.0 µg/L, but no mention is made of relative changes over time, which primary care, at least is concerned with in many cases.

    http://www.uspreventiveservicestaskforce.org/uspstf12/prostate/prostateart.htm
    http://www.bmj.com/content/341/bmj.c4543.full#T1
    http://www.auanet.org/content/media/COM-1552_MensHealthChecklistNoCrops.pdf

  4. Karolyn Devreese says:

    prostate cancer is really preventable with early diagnosis. Thus, consulting your doctor regulary is very essential. “”:”,

    Most up to date article provided by our blog site
    http://www.caramoantravel.com

  5. john dean says:

    now a days the proatate health concern is increasing world wide.And it should be promoted publicly and create awareness amongst common people . tell about the symptoms and cure to prevent the prostate ill health. And people should look for prostatitis immediate treatement when the symptoms occurs.

Leave a Reply

FROM THE VAULT

The Power of Small Why Doctors Shouldn't Be Healers Big Data in Healthcare. Good or Evil? Depends on the Dollars. California's Proposition 46 Narrow Networking

Masthead

Matthew Holt
Founder & Publisher

John Irvine
Executive Editor

Jonathan Halvorson
Editor

Alex Epstein
Director of Digital Media

Munia Mitra, MD
Chief Medical Officer

Vikram Khanna
Editor-At-Large, Wellness

Joe Flower
Contributing Editor

Michael Millenson
Contributing Editor

We're looking for bloggers. Send us your posts.

If you've had a recent experience with the U.S. health care system, either for good or bad, that you want the world to know about, tell us.

Have a good health care story you think we should know about? Send story ideas and tips to editor@thehealthcareblog.com.

ADVERTISE


Questions on reprints, permissions and syndication to ad_sales@thehealthcareblog.com.

THCB MARKETPLACE

Reach a super targeted healthcare audience with your text ad.
ad_sales@thehealthcareblog.com

ADVERTISEMENT

Log in - Powered by WordPress.